Tandem Diabetes Care stock
TNDMNASDAQTandem Diabetes Care, Inc., HealthcareISIN US8753722037
45Score 45 out of 100, Weak
Price and trend
66 / 100
Price history
−3.0% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 7.0% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 38% below its 52-week high. Largest decline in 13 years: 99% (January 2014 to November 2017).
Chart figures for advanced users
- SMA 50$17.41
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$18.84
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.82
- The lowest closing price of the last twelve months.
- Resistance$28.26
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Tandem Diabetes Care, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $1.22B, is number 53 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.01B (up 7.9% year on year) and a loss of $204.71M.
- For fiscal 2026, analysts expect on average revenue of $1.07B (up 5.7%) and adjusted earnings per share of −$0.67.
Show more
- MEQIRI Score 45 out of 100 (Weak): rank 473 of 714 in Healthcare, median 53.
- Our model puts fair value at $30.27, with the price 38% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- High debtDebt 5.45 times equity (latest quarter), Medical (Devices) median 0.47.Stability 26
- Loss-makingLoss of $49.24M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$36.3M over the last 12 months.Fundamentals 17
Its standout strengths are valuation and momentum, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price far below its 52-week high
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $20.18 and expensive above $60.55 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 10.2%. At 11.2% the fair value would be $26.25, at 9.2% it would be $35.81.
Possible value trap: looks cheap, but score below 50, high risk, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6.8% on the twelve months before. Revenue turned from negative at the start of the period to positive ($1.01B in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 52%, operating −8%, net −20%. Last 12 months: net −5%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Feb 2027in 98 days
- Last reported
- 5 Nov 2026EPS reported −$0.10 (expected −$0.25)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.670.0%
- Revenue
- $1.07B0.0%
- Earnings per share
- $0.130.0%
- Revenue
- $1.21B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +14.2%Guidance reaffirmed: sales of $1.065 billion to $1.085 billion, gross margin of 56% to 57%, adjusted EBITDA margin of 5% to 6%.
“We expect gross margins in the range of 56% to 57% and adjusted EBITDA margin of 5% to 6% of annual sales.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $32,555 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Twomey Christopher JSale
27 Oct 2026, Board
- Shares
- 1,700
- Price
- $19.15
- Value
- $32,555
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Tandem Diabetes Care
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 45
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- CONMEDCNMD $1.51B69
- EL.En.ELN.MI $1.48B75
- NovocureNVCR $1.4B30
- PROCEPT BioRoboticsPRCT $1.34B41
- Integra LifeSciences HoldingsIART $1.15B50
- Alphatec HoldingsATEC $1.14B34
- SI-BONESIBN $1.13B47
- IRadimedIRMD $1.11B77
ETFs that hold Tandem Diabetes Care
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 1.42% | 0.68% | €5.31M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.12% | 0.40% | €1.49B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.07% | 0.30% | €2.28B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.05% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.17B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.